The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...